Key Points
- Insider sale: Penumbra director Thomas Wilder sold 186 shares on January 2 at an average price of $310.72 for proceeds of $57,793.92, disclosed in an SEC filing.
- Earnings beat: On November 5 Penumbra reported $0.97 EPS (vs. $0.90 est.) and revenue of $354.69M (vs. $340.77M), with revenue up 17.8% year‑over‑year.
- Analyst sentiment & valuation: The stock has a consensus "Moderate Buy" with an average target of $340.40, trades near its 12‑month high (~$316) and carries a high PE of 75.59 on a $12.37B market cap.
Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Thomas Wilder sold 186 shares of the business's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $310.72, for a total value of $57,793.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Penumbra Stock Performance
Shares of PEN opened at $315.96 on Wednesday. The company has a current ratio of 6.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The firm has a market cap of $12.37 billion, a PE ratio of 75.59, a price-to-earnings-growth ratio of 1.92 and a beta of 0.71. The company's 50 day simple moving average is $289.92 and its 200-day simple moving average is $265.84. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $321.38.
Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. The firm had revenue of $354.69 million during the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. Penumbra's revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.85 EPS. As a group, equities analysts predict that Penumbra, Inc. will post 3.67 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on PEN shares. Robert W. Baird set a $345.00 price target on Penumbra in a report on Tuesday, December 16th. Wall Street Zen raised Penumbra from a "hold" rating to a "buy" rating in a research report on Saturday, December 20th. Evercore ISI reiterated an "outperform" rating and issued a $340.00 target price on shares of Penumbra in a research note on Monday. Royal Bank Of Canada reissued an "outperform" rating and issued a $355.00 target price on shares of Penumbra in a report on Wednesday, December 17th. Finally, Canaccord Genuity Group increased their price target on Penumbra from $355.00 to $359.00 and gave the stock a "buy" rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $340.40.
Check Out Our Latest Stock Analysis on Penumbra
Hedge Funds Weigh In On Penumbra
A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of Penumbra by 35.8% during the first quarter. Royal Bank of Canada now owns 19,332 shares of the company's stock valued at $5,169,000 after acquiring an additional 5,092 shares during the last quarter. United Services Automobile Association purchased a new position in Penumbra in the 1st quarter valued at about $656,000. Woodline Partners LP boosted its stake in shares of Penumbra by 476.1% during the 1st quarter. Woodline Partners LP now owns 145,881 shares of the company's stock worth $39,010,000 after purchasing an additional 120,558 shares during the last quarter. Bayforest Capital Ltd grew its holdings in shares of Penumbra by 35.9% during the first quarter. Bayforest Capital Ltd now owns 1,431 shares of the company's stock worth $383,000 after buying an additional 378 shares in the last quarter. Finally, Glenview Trust co acquired a new position in shares of Penumbra in the first quarter valued at approximately $230,000. 88.88% of the stock is owned by institutional investors and hedge funds.
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
